SPARC Q1 FY27 loss narrows to Rs 21 cr; revenue jumps fourfold YoY

Revenue Growth 20pctPat NegativeExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.4%Reaction day

₹212.40

prior close

₹218.48

announcement price

In-mkt

timing

Nifty Microcap 250market-0.1%-2.3% vs market

Pharmaceuticals peers, median of 165sector-0.1%-2.3% vs sector

On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-1.6

15m

-1.9

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.4-0.1-2.3-0.1-2.3

Next day

-3.3-0.2-3.1+0.0-3.4

-4.9+0.1-5.0-0.0-4.8

-3.5+0.3-3.8+0.3-3.8

-6.3+0.4-6.7-0.5-5.8

-6.7+0.5-7.2-1.1-5.5

-9.2+0.3-9.5-1.8-7.3

15d

-6.5+1.9-8.4+0.2-6.7

-7.3+2.2-9.5+1.7-9.0

-13.3-1.2-12.1-1.8-11.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SPARC Q1 FY27 standalone revenue rose to Rs 39.92 crore from Rs 9.64 crore year-on-year, aided by Rs 29.21 crore from termination of CMS licensing deal. Net loss narrowed to Rs 20.98 crore from Rs 52.03 crore. Total expenses rose to Rs 84.56 crore. Consolidated loss was Rs 20.78 crore. Board allotted 3.85 crore convertible warrants to Shanghvi Finance at Rs 155.80 each and approved reclassification of certain promoter group individuals to public. FY26 had a one-time Rs 1840 crore income from sale of a USFDA Priority Review Voucher for Sezaby.

Likely market impact

Loss narrowed but company remains unprofitable. Warrant issue to promoter entity and one-time PRV income lifted FY26. Watch revenue sustainability.